Avax Technologies Cancer Company Intelligence Report

Pharma Business Daily
Claim your FREE trial subscription!

Cancer:

Avax Technologies Cancer Company Intelligence Report

Espicom Business Intelligence
Market Briefing September 2005

Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. AVAX Technologies was incorporated on 12th January 1990, under the name Nehoc Inc. On 29th May 1992, it changed
its name to Appex Technologies Inc and, on 22nd October 1992, it merged into Walden Laboratories Inc, which was
incorporated on 18th September 1992. The company changed its name from Walden to AVAX Technologies Inc,
effective 26th March 1996.
AVAX is a biotechnology company with international operations, specialising in the development and commercialisation
of individualised therapies and other novel technologies primarily focused on cancer and other life-threatening
diseases.

Number of pages - 12

For full details, please email keithw@cmsinfo.com

Order Form

CMS, P&A House, Alma Road, Chesham, Bucks. HP5 3HB, UK
Tel: +44 (0)1494 771734
Fax: +44 (0)1494 778994
e-mail: Jennifer Cowlard

For more information about us, visit CMSinfo.